Business
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company’s first Chief Commercial Officer
Mr Tyson has both clinical experience treating patients with serious mental health disorders and 25 years of successful industry commercial experience in the
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"Mr Tyson has both clinical experience treating patients with serious mental health disorders and 25 years of successful industry commercial experience in the development and sales of medications in this fieldMr. Tyson is appointed as NRx anticipates approval of an ANDA for preservative-free ketamine and near term submission of a New Drug Application to expand ketamine labeling to encompass depression and suicidality. WILMINGTON, Del., April 13, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a biopharmaceutical company that focuses on neuroplastic therapies for depression, PTSD, and related conditions, today announces the appointment of Glenn Tyson as the company’s first Chief Commercial Officer. As NRx looks forward to the anticipated approval of its Abbreviated New Drug Application for their preservative-free ketamine product, it looks to build its commercial capabilities and prepare for a successful launch. Mr. Tyson has both clinical and commercial experience in addressing the needs of people suffering with serious mental illness. He began his career as a counselor in multiple settings working with children and adults with psychiatric conditions and addiction, before joining the pharmaceutical industry where he has spent 25 years developing expertise in all aspects of commercialization and sales. He served at GSK for 14 years in increasingly senior roles. He then joined Indivior as VP of Strategy and New Product Development, and then SVP of Sales and Marketing and subsequently President of Behavioral Health. He led Indivior in the successful launch of SUBLOCADE®, a once-monthly injectable for the treatment of opioid addiction, delivering 17 consecutive quarters of double-digit growth during his tenure. Most recently, Mr. Tyson has focused on the emerging sector of companies developing neuroplastic therapies for psychiatric conditions, including leadership level work with Transcend Therapeutics who recently announced a $700m deal with Otsuka. In addition to the pending ANDA application for Preservative Free Ketamine, NRx is preparing a New Drug Application under Fast Track Designation to expand the use of intravenous ketamine (NRX-100) to treat patients with severe depression, who may have suicidal ideation. The Company is also developing its D-Cycloserine asset (NRX-101), previously awarded Breakthrough Th...